Resource impact statement
No significant resource impact is anticipated
NICE has recommended nivolumab as an option for treating recurrent or metastatic squamous cell carcinoma of the head and neck in adults whose disease has progressed on platinum-based chemotherapy, only if:
- the disease has progressed within 6 months of having chemotherapy and
- the company provides it according to the commercial arrangement.
We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £9,000 per 100,000 population, based on a population for England of 56.3 million people).
This is because the population size is small, with around 500 people expected to be eligible for treatment each year, and the overall incremental cost of treatment is low.
Nivolumab has a discount that is commercial in confidence. It is the company’s responsibility to let relevant NHS organisations know details of the discount.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: